Statement

Feb 05, 2020

We are aware of the recent Ministry of Health (MoH) announcement, that five EU states (Belgium, the Netherlands, Luxembourg, Austria and Ireland) have issued a joint statement regarding our Global Managed Access Program (MAP). 
 
In December, we announced a global MAP to make AVXS-101 available to eligible patients in countries where it is not approved by regulatory authorities. We collaborated with an independent bioethics advisory committee, including a range of experts including clinicians, bioethicists, patient …